News

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigational von Willebrand disease (VWD) therapy VGA039. The…

The U.S. Food and Drug Administration (FDA) recently approved Journavx™ (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic developed to treat…

This inspiring event celebrates the exceptional individuals and organizations making a lasting impact in the bleeding disorders community. Trailblazing healthcare professionals and dedicated advocates were…

Did You Know? The name for a well-known bleeding disorder has a surprising origin tied to a 5-year-old boy from Canada. Learn why…

ITP is a rare autoimmune disorder that causes a significant reduction in platelets, which are necessary for clotting. Sanofi has announced positive…

Participate in Groundbreaking Michigan Study on Gene Therapy Awareness in the Hemophilia Community The National Bleeding Disorders Foundation is supporting an important…

The National Bleeding Disorders Foundation’s (NBDF) HANDI program has updated the online Patient Assistance Programs (PAPs) listing. The PAPs resource page encompasses programs designed to…

The U.S. Food and Drug Administration (FDA) has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce the frequency of bleeding…

In a significant advancement for von Willebrand Disease (VWD) research and treatment, an international team of experts, including patients, clinicians, and researchers,…

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigational von Willebrand disease (VWD) therapy VGA039. The…

The National Bleeding Disorders Foundation (NBDF) is excited to announce a new online, enduring, and accredited educational activity available to healthcare providers….

Are you ready to advocate for the bleeding disorders community? Join us at Washington Days 2025 for a powerful and impactful experience. Learn…

The T.H.R.I.V.E. campaign is an initiative to educate individuals with bleeding disorders and their support networks about six key steps for leading…

Bone health isn’t necessarily top of mind — especially at younger ages — but it should be. One study revealed that people with…

Chronic pain affects up to 58% of people with hemophilia, impacting mobility, mental health and daily activities. Recognizing this widespread issue, the…

The National Bleeding Disorders Foundation (NBDF) has announced that three new documents have been issued by the Medical and Scientific Advisory Council…

For thirty years, the Coalition for Hemophilia B has improved the quality of life for people with hemophilia B and their families…

A new study sheds light on the challenges of diagnosing and managing gastrointestinal (GI) bleeding in individuals with severe von Willebrand disease…

CHOP Researchers Investigate Durability of Hemophilia A Gene Therapy Findings of a new preclinical study published online in Nature Communications may help address lingering…

On October 11, 2024, Pfizer announced that the U.S. FDA approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency…

 new preclinical study led by CHOP researchers, published in Nature Communications, offers promising insights into the long-term effectiveness of hemophilia A gene therapy….

The World Federation of Hemophilia (WFH) announced the 2025 World Hemophilia Day theme: Access for All: Women and Girls Bleed Too. Learn…

Phil Gattone said, “We greatly appreciate Pfizer’s innovative efforts in developing this novel treatment option that addresses some of the ongoing challenges…

Dive into NBDF’s August 2024 Government Relations Update for essential information on Medicaid unwinding, ACA premium tax credits, NIH reform, and state-level…